Compare IPSC & IOBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | IOBT |
|---|---|---|
| Founded | 2019 | 2014 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.3M | 57.2M |
| IPO Year | 2021 | 2021 |
| Metric | IPSC | IOBT |
|---|---|---|
| Price | $1.26 | $0.63 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 4 |
| Target Price | $3.00 | ★ $3.50 |
| AVG Volume (30 Days) | ★ 1.5M | 695.2K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $113,337,000.00 | N/A |
| Revenue This Year | $1,590.09 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4122.69 | N/A |
| 52 Week Low | $0.34 | $0.32 |
| 52 Week High | $1.19 | $2.79 |
| Indicator | IPSC | IOBT |
|---|---|---|
| Relative Strength Index (RSI) | 76.36 | 44.08 |
| Support Level | $0.90 | $0.60 |
| Resistance Level | $1.05 | $0.70 |
| Average True Range (ATR) | 0.14 | 0.07 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 96.15 | 40.40 |
Century Therapeutics Inc is a biotechnology company that specializes in leveraging adult stem cells to develop cell therapy products aimed at treating cancer, autoimmune disorders, and inflammatory diseases. Their features a genetically engineered allogeneic cell therapy platform that incorporates induced pluripotent stem cells (iPSCs), CRISPR-mediated precision gene editing, proprietary chimeric antigen receptors (CARs), Allo-EvasionTM technology, and manufacturing capabilities. This comprehensive platform seeks to address the limitations of first-generation cell therapies by optimizing cell product performance, preventing rejection by the host immune system, and reducing development and supply risks.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.